Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy

Aristotelis G. Anastasiadis, Debra L. Bemis, Brian C. Stisser, Laurent Salomon, Mohamed A. Ghafar, Ralph Buttyan

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


The accumulation of cancerous cells within a growing prostate tumor can deprive them of adequate vascular support. Without this support, the affected tumor cells become hypoxic, a condition that is usually unfavorable for the further growth and survival of eukaryotic cells. Mammalian cells, however, have the ability of responding to a hypoxic environment by activating a "hypoxia-response" signaling system. Ultimately, this signaling system upregulates the expression of a network of gene products that increase the propensity of the cell to survive even in this adverse environment. With increasing evidence that hypoxia and an activated hypoxia-response signaling system can influence progression (via increased angiogenic propensity and apoptotic resistance) and the therapeutic responsiveness of prostate cancer cells, this review will examine the concept of targeting hypoxia or the hypoxia-response system of prostate tumor cells as a means to suppress prostate tumor progression and metastasis or perhaps even as a means for eliminating prostate tumors in advanced prostate cancer patients.

Original languageEnglish
Pages (from-to)191-196
Number of pages6
JournalCurrent Drug Targets
Issue number3
StatePublished - Apr 2003
Externally publishedYes


  • Akt/Protein kinase B
  • Angiogenesis
  • Apoptosis
  • Hypoxia
  • Hypoxia inducible factor-1α (HIF-1α)
  • Prostate cancer
  • VEGF


Dive into the research topics of 'Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy'. Together they form a unique fingerprint.

Cite this